Prelude Capital Management’s Pandion Therapeutics Inc. Common Stock PAND Stock Holding History

Prelude Capital Management’s Portfolio PAND Stock Details PAND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-12,185	Closed	-$732K	–	2175
2021 Q1	$732K	Buy	+12,185	New	+$441K	0.02%	726

Prelude Capital Management's PAND Position: Q2 2021 in Review

Prelude Capital Management sold out of Pandion Therapeutics Inc. Common Stock (PAND) in Q2 2021, closing a stake of 12,185 shares — an estimated $732K sold.

Prelude Capital Management first reported a position in PAND in Q1 2021 and held it in 1 quarter. The position peaked at $732K in Q1 2021. 0 funds tracked by Wall St. Rank hold PAND as of Q2 2021.

Prelude Capital Management reported no remaining Pandion Therapeutics Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
Prelude Capital Management sold 12,185 Pandion Therapeutics Inc. Common Stock shares in Q2 2021, an estimated $732K.
Prelude Capital Management first reported a position in Pandion Therapeutics Inc. Common Stock in Q1 2021 and held it in 1 quarter.
Prelude Capital Management's Pandion Therapeutics Inc. Common Stock position peaked at $732K in Q1 2021.
0 funds tracked by Wall St. Rank held Pandion Therapeutics Inc. Common Stock as of Q2 2021.

Based on Prelude Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.